Kinnate Biopharma announced that the FDA has granted Fast Track designation for Kinnate’s investigational pan-FGFR inhibitor, KIN-3248, for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma, or CCA, harboring fibroblast growth factor receptor 2 gene fusions or other alterations, who have received at least one prior systemic therapy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KNTE:
- Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
- Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
- Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
- Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
